- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01779830
A Study of LY2624803 in Participants With Transient Insomnia
January 28, 2013 updated by: Eli Lilly and Company
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Crossover Study of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Subjects
The aim of this study is to learn how different doses of LY2624803 affect sleep in healthy people.
The study has four treatment periods.
Participants will receive a single dose of LY2624803, another sleeping pill, or placebo in each treatment period.
The study will last approximately 1 month for each participant.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rouffach, France
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Overtly healthy males or females
- Women of child-bearing potential, who test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control during the study and for one month following the last dose of study drug
- Between the Body Mass Index (BMI) of 19 and 30 kilogram per meter square (kg/m^2), inclusive
- Normal bedtime hours, with routine time spent in bed between 6.5 hours and 9 hours each night
- Participants whose daily caffeine intake permits maintenance of normal bed time hours
- Non response to placebo defined as a Wake After Sleep Onset (WASO) of greater than or equal to 45 minutes, on a 5-hour phase-advanced polysomnography (PSG) screening night after bedtime single-blind placebo administration
- Males must agree to use effective barrier contraception during the course of the trial and 3 months later
- Participants over 65 years of age, on a stable dose of one medication for lowering cholesterol, triglycerides and/or one medication for lowering blood pressure and/or substitutive hormonal therapy in post menopausal women are allowed provided those treatments have no central effect
- Clinical laboratory test results within normal reference range judged to be not clinically significant
- Normal sitting blood pressure and pulse rate as determined
- Venous access sufficient to allow blood sampling
- Are reliable and willing to make themselves available for the duration of the study
- Have given written informed consent approved by Lilly and the ethical review board governing the site
Exclusion Criteria:
- Shift workers (those who shifted work within 7 days of any PSG night) or any person who has crossed (or will have crossed) more than one time zone by aircraft within 3 days prior to entry
- Rhinoconjunctivitis, urticaria or chronic pain severe enough to interfere with sleep
- Nocturia that would interfere with sleep assessment
- Participants with allergic conjunctivitis or urticaria
- Regular napping (greater than (≥) 2 daytime naps/week by history)
- Symptoms consistent with a sleep disorder or history of same
- Sleep disorders detected during the screening night
- Evidence of significant active neuropsychiatric disease and in particular evidence of significant medical or psychiatric illness within the past 12 months that could contribute to insomnia
- Irregular or altered sleep/wake schedule
- Known history of fainting or low blood pressure. History of cranial trauma and loss of consciousness will be discussed prior to including any such participant
- Within 3 months of the initial dose of study drug, have received treatment with a drug that has not received regulatory approval for any indication
- Participants with postural hypotension at screening
- Participants with a history of postural hypotension, loss of consciousness, explained or unexplained syncope or seizure episodes or a family history of seizures. History of a single febrile convulsion is acceptable
- Known allergies to LY2624803, Zolpidem or related compounds
- Persons who have previously completed or withdrawn from this study or any other study investigating LY2624803
- An abnormality in the 12-lead electrocardiogram (ECG) that increases the risks associated with participating in the study
- History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurocardiogenic or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
- Any other condition with in the opinion of the investigator would preclude participation the study
- Regular use of known drugs of abuse and/or positive findings on urinary drug screening
- Evidence of Human Immunodeficiency Virus (HIV) and/or positive human HIV antibodies
- Evidence of hepatitis C and/or positive hepatitis C antibody
- Evidence of hepatitis B and/or positive hepatitis B surface antigen
- Women with a positive pregnancy test
- Women who are lactating
- Use of prescription, over the counter or herbal medications that cannot safely be discontinued within 28 days prior to enrollment
- Blood donation of more than 500 milliliter (mL) within the last month
- History of smoking within the previous 6 months of screening
- Participants who have an average weekly alcohol intake that exceeds 28 units per week (males) and 21 units per week (females), or participants unwilling to stop alcohol consumption for the duration of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 0.3 mg LY2624803
Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
|
Administered orally as capsules.
Other Names:
|
EXPERIMENTAL: 3.0 mg LY2624803
Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
|
Administered orally as capsules.
Other Names:
|
EXPERIMENTAL: 6.0 mg LY2624803
Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
|
Administered orally as capsules.
Other Names:
|
ACTIVE_COMPARATOR: 10 mg Zolpidem
Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
|
Administered orally as tablets.
|
PLACEBO_COMPARATOR: Placebo
Single dose of placebo administered orally in up to 1 of 4 treatment periods.
|
Administered orally as capsules.
Administered orally as tablets.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo
Time Frame: Baseline up to Day 60
|
Baseline up to Day 60
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Latency to Persistent Sleep (LPS) with LY2624803 Compared to Placebo
Time Frame: Baseline up to Day 60
|
Baseline up to Day 60
|
Total Sleep Time (TST) with LY2624803 Compared to Placebo
Time Frame: Baseline up to Day 60
|
Baseline up to Day 60
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (ACTUAL)
November 1, 2008
Study Completion (ACTUAL)
November 1, 2008
Study Registration Dates
First Submitted
January 25, 2013
First Submitted That Met QC Criteria
January 28, 2013
First Posted (ESTIMATE)
January 30, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
January 30, 2013
Last Update Submitted That Met QC Criteria
January 28, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Hypnotics and Sedatives
- GABA Agents
- Sleep Aids, Pharmaceutical
- GABA-A Receptor Agonists
- GABA Agonists
- Zolpidem
Other Study ID Numbers
- 12057
- I2K-MC-ZZAA (OTHER: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Transient Insomnia
-
Philips RespironicsCompletedInsomnia | Sleeplessness | Transient InsomniaUnited States
-
Bod AustraliaWoolcock Institute of Medical ResearchCompletedInsomnia | Sleep Disturbance | Insomnia Type; Sleep Disorder | Insomnia, Transient | Insomnia Due to Anxiety and Fear | Insomnia Due to Other Mental DisorderAustralia
-
Sequential Medicine LtdWithdrawn
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedA 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase AdvanceTransient InsomniaUnited States
-
TakedaCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedTransient InsomniaUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedTransient InsomniaUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedTransient InsomniaUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedTransient InsomniaUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedTransient InsomniaUnited States
Clinical Trials on LY2624803 - Capsules
-
Eli Lilly and CompanyTerminatedInsomniaRussian Federation, Germany, Hungary
-
Eli Lilly and CompanyCompletedSleep Initiation and Maintenance DisordersJapan
-
Reata, a wholly owned subsidiary of BiogenAbbVie; Friedreich's Ataxia Research AllianceActive, not recruitingFriedreich AtaxiaUnited States, Australia, Austria, Italy, United Kingdom
-
Reata, a wholly owned subsidiary of BiogenAbbVieCompletedMItochondrial MyopathiesUnited States, Denmark
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
AbbottQuintiles, Inc.Terminated
-
Reata, a wholly owned subsidiary of BiogenTerminatedConnective Tissue Disease-Associated Pulmonary Arterial HypertensionUnited States, Spain, Japan, Australia, United Kingdom, Canada, Germany, Belgium, Argentina, Israel, Mexico, Brazil, Czechia, Netherlands, Philippines
-
Montefiore Medical CenterCompletedIrritable Bowel SyndromeUnited States
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Imperial College London4D pharma plcActive, not recruitingMelanoma | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Renal Cancer | Urethral Cancer | Uterine CancerUnited Kingdom